IMC statement on delayed implementation of changes to Patented Medicines Regulations
Ottawa, June 1, 2020 – Innovative Medicines Canada released the following statement today in response to the announcement by Health Canada that implementation of the amendments to the Patented Medicines Regulations will be delayed to January 1, 2021.
“We welcome the delayed implementation of amendments to the Patented Medicines Regulations.
“Today’s announcement means that Canada’s innovative medicines sector can focus on continuing the fight against COVID-19 without unnecessary distraction.
“Delaying the implementation also means that the Patented Medicine Prices Review Board (PMPRB) has more time to adequately consult industry on the guidelines, and to evaluate their impact on the Canadian healthcare system.
“The innovative medicines sector remains deeply concerned about the impact the amendments to the Patented Medicines Regulations, as they are currently drafted, will have on Canadians’ access to new medications and treatments, and on Canada’s ability to attract investment to the life sciences sector.
“We look forward to more details about the PMPRB’s next steps regarding the consultation process.”
About Innovative Medicines Canada
Innovative Medicines Canada is the national voice of Canada’s innovative pharmaceutical industry. We advocate for policies that enable the discovery, development and commercialization of innovative medicines and vaccines that improve the lives of all Canadians. We support our members’ commitment to being valued partners in the Canadian healthcare system.
– 30 –
For further information:
Director, Media and Public Relations